Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups

Digestive and Liver Disease

Volumn 47, Issue 12, 2015, Pages 997-1006

  Lonardo, Amedeo ^a   Bellentani, Stefano ^a   Argo, Curtis K ^b   Ballestri, Stefano ^a   Byrne, Christopher D ^c   Caldwell, Stephen H ^b   Cortez Pinto, Helena ^d   Grieco, Antonio ^e   Machado, Mariana V ^d   Miele, Luca ^e   Targher, Giovanni ^f  

^a AUSL Modena   (Italy)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Dyslipidaemia; Metabolic syndrome; NAFLD; Obesity; Type 2 diabetes mellitus

Indexed keywords

ALPHA TOCOPHEROL; EXENDIN 4; EZETIMIBE; LIRAGLUTIDE; LOSARTAN; METFORMIN; OBETICHOLIC ACID; PIOGLITAZONE; TELMISARTAN;

ARTICLE; ETHNIC DIFFERENCE; EXERCISE; FAMILIAL HYPOBETALIPOPROTEINEMIA; FAMILY HISTORY; FAMILY STUDY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOCHOLESTEROLEMIA; HYPOLIPEMIA; INTRAABDOMINAL FAT; LOW CALORY DIET; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MOLECULAR GENETICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; AGE; COMPLICATION; ETHNIC GROUP; GENETICS; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR;

AGE FACTORS; DIABETES MELLITUS, TYPE 2; ETHNIC GROUPS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RISK FACTORS; SEX FACTORS;

EID: 84983123731     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.08.004     Document Type: Article

References (200)

1. Scaglioni F., Ciccia S., Marino M., et al. ASH and NASH. Digestive Diseases 2011, 29:202-210.
2. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
3. Targher G., Chonchol M., Miele L., et al. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Seminars in Thrombosis and Hemostasis 2009, 35:277-287.
4. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature Reviews Gastroenterology & Hepatology 2013, 10:330-344.
5. Machado M.V., Cortez-Pinto H. Management of fatty liver disease with the metabolic syndrome. Expert Review of Gastroenterology & Hepatology 2014, 8:487-500.
6. Lonardo A., Ballestri S., Marchesini G., et al. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Digestive and Liver Disease 2015, 47:181-190.
7. Lonardo A., Sookoian S., Chonchol M., et al. Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Current Pharmaceutical Design 2013, 19:5177-5192.
8. Byrne C.D., Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2014, 34:1155-1161.
9. Baumeister S.E., Volzke H., Marschall P., et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008, 134:85-94.
10. Argo C.K., Caldwell S.H. Epidemiology and natural history of non-alcoholic steatohepatitis. Clinics in Liver Disease 2009, 13:511-531.
11. Musso G., Gambino R., Cassader M., et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine 2011, 43:617-649.
12. Nascimbeni F., Pais R., Bellentani S., et al. From NAFLD in clinical practice to answers from guidelines. Journal of Hepatology 2013, 59:859-871.
13. Lonardo A. Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going?. Digestive Diseases 1999, 17:80-89.
14. Machado M.V., Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World Journal of Gastroenterology 2014, 20:12956-12980.
15. Loria P., Adinolfi L.E., Bellentani S., et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Digestive and Liver Disease 2010, 42:272-282.
16. Fan J.G., Zhu J., Li X.J., et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. Journal of Hepatology 2005, 43:508-514.
17. Lonardo A., Lombardini S., Scaglioni F., et al. Fatty liver, carotid disease and gallstones: a study of age-related associations. World Journal of Gastroenterology 2006, 12:5826-5833.
18. Hu X., Huang Y., Bao Z., et al. Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units. BMC Gastroenterology 2012, 12:123.
19. Eguchi Y., Hyogo H., Ono M., et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. Journal of Gastroenterology 2012, 47:586-595.
20. Wang Z., Xu M., Hu Z., et al. Sex-specific prevalence of fatty liver disease and associated metabolic factors in Wuhan, south central China. European Journal of Gastroenterology and Hepatology 2014, 26:1015-1021.
21. Lee J.Y., Kim K.M., Lee S.G., et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. Journal of Hepatology 2007, 47:239-244.
22. Zhou Y.J., Li Y.Y., Nie Y.Q., et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World Journal of Gastroenterology 2007, 13:6419-6424.
23. Caballeria L., Pera G., Auladell M.A., et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. European Journal of Gastroenterology and Hepatology 2010, 22:24-32.
24. Shen L., Fan J.G., Shao Y., et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World Journal of Gastroenterology 2003, 9:1106-1110.
25. Zelber-Sagi S., Nitzan-Kaluski D., Halpern Z., et al. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver International 2006, 26:856-863.
26. Wong V.W., Chu W.C., Wong G.L., et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012, 61:409-415.
27. Chen C.H., Huang M.H., Yang J.C., et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. Journal of Clinical Gastroenterology 2006, 40:745-752.
28. Foster T., Anania F.A., Li D., et al. The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA). Digestive Diseases and Sciences 2013, 58:2392-2398.
29. Xu C., Yu C., Ma H., et al. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. American Journal of Gastroenterology 2013, 108:1299-1304.
30. Yang W., Huang H., Wang Y., et al. High red blood cell distribution width is closely associated with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology 2014, 26:174-178.
31. Park S.H., Jeon W.K., Kim S.H., et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. Journal of Gastroenterology and Hepatology 2006, 21:138-143.
32. Wang Z., Xu M., Peng J., et al. Prevalence and associated metabolic factors of fatty liver disease in the elderly. Experimental Gerontology 2013, 48:705-709.
33. Koehler E.M., Schouten J.N., Hansen B.E., et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. Journal of Hepatology 2012, 57:1305-1311.
34. Younossi Z.M., Stepanova M., Negro F., et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 2012, 91:319-327.
35. Frith J., Day C.P., Henderson E., et al. Non-alcoholic fatty liver disease in older people. Gerontology 2009, 55:607-613.
36. Noureddin M., Yates K.P., Vaughn I.A., et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 2013, 58:1644-1654.
37. Singh D.K., Sakhuja P., Malhotra V., et al. Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis. Digestive Diseases and Sciences 2008, 53:1967-1976.
38. Bambha K., Belt P., Abraham M., et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012, 55:769-780.
39. Tapper E.B., Krajewski K., Lai M., et al. Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease. Gastroenterology Reports 2014, 2:276-280.
40. Hossain N., Afendy A., Stepanova M., et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology 2009, 7:1224-1229. 1229.e1-2.
41. Argo C.K., Northup P.G., Al-Osaimi A.M., et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. Journal of Hepatology 2009, 51:371-379.
42. Yang J.D., Abdelmalek M.F., Pang H., et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014, 59:1406-1414.
43. Bertolotti M., Lonardo A., Mussi C., et al. Nonalcoholic fatty liver disease and aging: epidemiology to management. World Journal of Gastroenterology 2014, 20:14185-14204.
44. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
45. Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. Journal of Hepatology 2008, 49:608-612.
46. Rafiq N., Bai C., Fang Y., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clinical Gastroenterology and Hepatology 2009, 7:234-238.
47. Stepanova M., Rafiq N., Makhlouf H., et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Digestive Diseases and Sciences 2013, 58:3017-3023.
48. Bedogni G., Miglioli L., Masutti F., et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007, 46:1387-1391.
49. Haring R., Wallaschofski H., Nauck M., et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009, 50:1403-1411.
50. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
51. Weston S.R., Leyden W., Murphy R., et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005, 41:372-379.
52. Lazo M., Hernaez R., Eberhardt M.S., et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. American Journal of Epidemiology 2013, 178:38-45.
53. Tota-Maharaj R., Blaha M.J., Zeb I., et al. Ethnic and sex differences in fatty liver on cardiac computed tomography: the multi-ethnic study of atherosclerosis. Mayo Clinic Proceedings 2014, 89:493-503.
54. Kallwitz E.R., Guzman G., TenCate V., et al. The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients. American Journal of Gastroenterology 2009, 104:64-69.
55. Dongiovanni P., Anstee Q.M., Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Current Pharmaceutical Design 2013, 19:5219-5238.
56. Struben V.M., Hespenheide E.E., Caldwell S.H. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. American Journal of Medicine 2000, 108:9-13.
57. Willner I.R., Waters B., Patil S.R., et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. American Journal of Gastroenterology 2001, 96:2957-2961.
58. Tokushige K., Yatsuji S., Hashimoto E., et al. Familial aggregation in patients with non-alcoholic steatohepatitis. Internal Medicine 2008, 47:405-410.
59. Brouwers M.C., Cantor R.M., Kono N., et al. Heritability and genetic loci of fatty liver in familial combined hyperlipidemia. Journal of Lipid Research 2006, 47:2799-2807.
60. Abdelmalek M.F., Liu C., Shuster J., et al. Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology 2006, 4:1162-1169.
61. Schwimmer J.B., Celedon M.A., Lavine J.E., et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009, 136:1585-1592.
62. Bathum L., Petersen H.C., Rosholm J.U., et al. Evidence for a substantial genetic influence on biochemical liver function tests: results from a population-based Danish twin study. Clinical Chemistry 2001, 47:81-87.
63. Makkonen J., Pietilainen K.H., Rissanen A., et al. Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. Journal of Hepatology 2009, 50:1035-1042.
64. Loomba R., Rao F., Zhang L., et al. Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology 2010, 139:836-845. 845.e1.
65. Jermendy G., Horvath T., Littvay L., et al. Effect of genetic and environmental influences on cardiometabolic risk factors: a twin study. Cardiovascular Diabetology 2011, 10:96.
66. Tarnoki A.D., Tarnoki D.L., Bata P., et al. Heritability of non-alcoholic fatty liver disease and association with abnormal vascular parameters: a twin study. Liver International 2012, 32:1287-1293.
67. Zarrinpar A., Gupta S., Maurya M.R., et al. Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut 2015, 10.1136/gutjnl-2015-309456.
68. Singal A.G., Manjunath H., Yopp A.C., et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. American Journal of Gastroenterology 2014, 109:325-334.
69. Sookoian S., Castano G.O., Burgueno A.L., et al. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. Journal of Lipid Research 2009, 50:2111-2116.
70. Speliotes E.K., Butler J.L., Palmer C.D., et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010, 52:904-912.
71. Valenti L., Al-Serri A., Daly A.K., et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51:1209-1217.
72. Rotman Y., Koh C., Zmuda J.M., et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010, 52:894-903.
73. Valenti L., Alisi A., Galmozzi E., et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010, 52:1274-1280.
74. Beer N.L., Tribble N.D., McCulloch L.J., et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Human Molecular Genetics 2009, 18:4081-4088.
75. Petta S., Miele L., Bugianesi E., et al. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLOS ONE 2014, 9:e87523.
76. Speliotes E.K., Yerges-Armstrong L.M., Wu J., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLOS Genetics 2011, 7:e1001324.
77. Gorden A., Yang R., Yerges-Armstrong L.M., et al. Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity. Human Heredity 2013, 75:34-43.
78. Nobili V., Donati B., Panera N., et al. A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease. Journal of Pediatric Gastroenterology and Nutrition 2014, 58:632-636.
79. Petta S., Grimaudo S., Camma C., et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. Journal of Hepatology 2012, 56:1356-1362.
80. Miele L., Beale G., Patman G., et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 2008, 135. 282-91.e1.
81. Sookoian S., Castano G.O., Scian R., et al. Genetic variation in TM6SF2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 2015, 61:515-525.
82. Fawcett K.A., Grimsey N., Loos R.J., et al. Evaluating the role of LPIN1 variation in insulin resistance, body weight, and human lipodystrophy in UK populations. Diabetes 2008, 57:2527-2533.
83. Valenti L., Motta B.M., Alisi A., et al. LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. Journal of Pediatric Gastroenterology and Nutrition 2012, 54:588-593.
84. Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
85. Reaven G.M. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
86. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
87. Byrne C.D., Olufadi R., Bruce K.D., et al. Metabolic disturbances in non-alcoholic fatty liver disease. Clinical Science (London) 2009, 116:539-564.
88. Byrne C.D. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabetic Medicine 2012, 29:1098-1107.
89. Targher G., Byrne C.D. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. Journal of Clinical Endocrinology and Metabolism 2013, 98:483-495.
90. Armstrong M.J., Adams L.A., Canbay A., et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014, 59:1174-1197.
91. Singh S., Allen A.M., Wang Z., et al. Fibrosis progression in nonalcoholic fatty liver vs. non-alcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clinical Gastroenterology and Hepatology 2015, 13:643-654.
92. Sung K.C., Wild S.H., Byrne C.D. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. Journal of Hepatology 2014, 60:1040-1045.
93. Ryoo J.H., Suh Y.J., Shin H.C., et al. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. Journal of Gastroenterology and Hepatology 2014, 29:1926-1931.
94. Loria P., Lonardo A., Lombardini S., et al. Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. Journal of Gastroenterology and Hepatology 2005, 20:1176-1184.
95. Perlstein T.S., Gumieniak O., Williams G.H., et al. Uric acid and the development of hypertension: the normative aging study. Hypertension 2006, 48:1031-1036.
96. Afzali A., Weiss N.S., Boyko E.J., et al. Association between serum uric acid level and chronic liver disease in the United States. Hepatology 2010, 52:578-589.
97. Keenan T., Blaha M.J., Nasir K., et al. Relation of uric acid to serum levels of high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis. American Journal of Cardiology 2012, 110:1787-1792.
98. Xu J., Peng H., Ma Q., et al. Associations of non-high density lipoprotein cholesterol and traditional blood lipid profiles with hyperuricemia among middle-aged and elderly Chinese people: a community-based cross-sectional study. Lipids in Health and Disease 2014, 13:117.
99. Lonardo A., Loria P., Leonardi F., et al. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Digestive and Liver Disease 2002, 34:204-211.
100. Kuo C.F., Yu K.H., Luo S.F., et al. Gout and risk of non-alcoholic fatty liver disease. Scandinavian Journal of Rheumatology 2010, 39:466-471.
101. Hwang I.C., Suh S.Y., Suh A.R., et al. The relationship between normal serum uric acid and nonalcoholic fatty liver disease. Journal of Korean Medical Science 2011, 26:386-391.
102. Petta S., Cammà C., Cabibi D., et al. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics 2011, 34:757-766.
103. Ryu S., Chang Y., Kim S.G., et al. Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. Metabolism: Clinical and Experimental 2011, 60:860-866.
104. Vos M.B., Colvin R., Belt P., et al. Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. Journal of Pediatric Gastroenterology and Nutrition 2012, 54:90-96.
105. Sirota J.C., McFann K., Targher G., et al. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism: Clinical and Experimental 2013, 62:392-399.
106. Xu C., Yu C., Xu L., et al. High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. PLoS ONE 2010, 5:e11578.
107. Xie Y., Wang M., Zhang Y., et al. Serum uric acid and non-alcoholic fatty liver disease in non-diabetic Chinese men. PLoS ONE 2013, 8:e67152.
108. Kotronen A., Westerbacka J., Bergholm R., et al. Liver fat in the metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 2007, 92:3490-3497.
109. Kotronen A., Juurinen L., Hakkarainen A., et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 2008, 31:165-169.
110. Ryysy L., Hakkinen A.M., Goto T., et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000, 49:749-758.
111. Maximos M., Bril F., Portillo Sanchez P., et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology 2015, 61:153-160.
112. Portillo-Sanchez P., Bril F., Maximos M., et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. Journal of Clinical Endocrinology and Metabolism 2015, 100:2231-2238.
113. Michelotti G.A., Machado M.V., Diehl A.M. NAFLD, NASH and liver cancer. Nature Reviews Gastroenterology & Hepatology 2013, 10:656-665.
114. de Marco R., Locatelli F., Zoppini G., et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999, 22:756-761.
115. Porepa L., Ray J.G., Sanchez-Romeu P., et al. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. Canadian Medical Association Journal 2010, 182:E526-E531.
116. Campbell P.T., Newton C.C., Patel A.V., et al. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 2012, 35:1835-1844.
117. Zoppini G., Fedeli U., Gennaro N., et al. Mortality from chronic liver diseases in diabetes. American Journal of Gastroenterology 2014, 109:1020-1025.
118. Adams L.A., Harmsen S., St Sauver J.L., et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. American Journal of Gastroenterology 2010, 105:1567-1573.
119. Targher G., Bertolini L., Rodella S., et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007, 30:2119-2121.
120. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New England Journal of Medicine 2010, 363:1341-1350.
121. Targher G., Chonchol M.B., Byrne C.D. CKD and nonalcoholic fatty liver disease. American Journal of Kidney Diseases 2014, 64:638-652.
122. Targher G., Bertolini L., Rodella S., et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008, 51:444-450.
123. Targher G., Chonchol M., Bertolini L., et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. Journal of the American Society of Nephrology 2008, 19:1564-1570.
124. Centre WHOM Obesity and overweight 2013, Centre WHOM, Geneva, Switzerland.
125. Nguyen D.M., El-Serag H.B. The epidemiology of obesity. Gastroenterology Clinics of North America 2010, 39:1-7.
126. Tsigos C., Hainer V., Basdevant A., et al. Management of obesity in adults: European clinical practice guidelines. Obesity Facts 2008, 1:106-116.
127. Sturm R. Increases in clinically severe obesity in the United States, 1986-2000. Archives of Internal Medicine 2003, 163:2146-2148.
128. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
129. Bellentani S., Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. Journal of Hepatology 2001, 35:531-537.
130. Fabbrini E., Sullivan S., Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010, 51:679-689.
131. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology and Therapeutics 2011, 34:274-285.
132. Machado M., Marques-Vidal P., Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. Journal of Hepatology 2006, 45:600-606.
133. Zelber-Sagi S., Lotan R., Shlomai A., et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. Journal of Hepatology 2012, 56:1145-1151.
134. Junior W.S., Nonino-Borges C.B. Clinical predictors of different grades of nonalcoholic fatty liver disease. Obesity Surgery 2012, 22:248-252.
135. Angulo P., Keach J.C., Batts K.P., et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30:1356-1362.
136. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine 2003, 348:1625-1638.
137. Kabir M., Catalano K.J., Ananthnarayan S., et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. American Journal of Physiology. Endocrinology and Metabolism 2005, 288:E454-E461.
138. Wajchenberg B.L., Giannella-Neto D., da Silva M.E., et al. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Hormone and Metabolic Research 2002, 34:616-621.
139. Rocha P.M., Barata J.T., Minderico C.S., et al. Visceral abdominal and subfascial femoral adipose tissue have opposite associations with liver fat in overweight and obese premenopausal Caucasian women. Journal of Lipids 2011, 2011:154672.
140. van der Poorten D., Samer C.F., Ramezani-Moghadam M., et al. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause. Hepatology 2013, 57:2180-2188.
141. Wong R.J., Ahmed A. Obesity and non-alcoholic fatty liver disease: disparate associations among Asian populations. World Journal of Hepatology 2014, 6:263-273.
142. Colak Y., Karabay C.Y., Tuncer I., et al. Relation of epicardial adipose tissue and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology 2012, 24:613-618.
143. Iacobellis G., Barbarini G., Letizia C., et al. Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity (Silver Spring) 2014, 22:332-336.
144. Granér M., Nyman K., Siren R., et al. Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease. Circulation: Cardiovascular Imaging 2014, 8:e001979.
145. Petta S., Argano C., Colomba D., et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. Journal of Hepatology 2015, 62:928-933.
146. Cheung O., Kapoor A., Puri P., et al. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology 2007, 46:1091-1100.
147. Ulucan S., Katlandur H., Kaya Z. Epicardial fat and liver disease; the contribution of cardio autonomic nervous system function. Journal of Hepatology 2015, 62:1214.
148. Pagadala M.R., McCullough A.J. Non-alcoholic fatty liver disease and obesity: not all about body mass index. American Journal of Gastroenterology 2012, 107:1859-1861.
149. Bluher M. The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Current Opinion in Lipidology 2010, 21:38-43.
150. Hinnouho G.M., Czernichow S., Dugravot A., et al. Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter. Diabetes Care 2013, 36:2294-2300.
151. Park Y.W., Zhu S., Palaniappan L., et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Archives of Internal Medicine 2003, 163:427-436.
152. Consultation W.H.O.E. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004, 363:157-163.
153. Ruderman N., Chisholm D., Pi-Sunyer X., et al. The metabolically obese, normal-weight individual revisited. Diabetes 1998, 47:699-713.
154. Messier V., Karelis A.D., Robillard M.E., et al. Metabolically healthy but obese individuals: relationship with hepatic enzymes. Metabolism: Clinical and Experimental 2010, 59:20-24.
155. Thelwall P.E., Smith F.E., Leavitt M.C., et al. Hepatic cholesteryl ester accumulation in lysosomal acid lipase deficiency: non-invasive identification and treatment monitoring by magnetic resonance. Journal of Hepatology 2013, 59:543-549.
156. Reiner Ž., Guardamagna O., Nair D., et al. Lysosomal acid lipase deficiency - an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis 2014, 235:21-30.
157. Balwani M., Breen C., Enns G.M., et al. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. Hepatology 2013, 58:950-957.
158. Valayannopoulos V., Malinova V., Honzík T., et al. Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. Journal of Hepatology 2014, 61:1135-1142.
159. Fallo F., Dalla Pozza A., Sonino N., et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutrition, Metabolism and Cardiovascular Diseases 2009, 19:646-653.
160. Zhang H., He S.M., Sun J., et al. Prevalence and etiology of abnormal liver tests in an adult population in Jilin, China. International Journal of Medical Sciences 2011, 8:254-262.
161. Hou X.H., Zhu Y.X., Lu H.J., et al. Non-alcoholic fatty liver disease's prevalence and impact on alanine aminotransferase associated with metabolic syndrome in the Chinese. Journal of Gastroenterology and Hepatology 2011, 26:722-730.
162. Liao X.H., Cao X., Liu J., et al. Prevalence and features of fatty liver detected by physical examination in Guangzhou. World Journal of Gastroenterology 2013, 19:5334-5339.
163. Lonardo A., Bellini M., Tartoni P., et al. The 'bright liver' syndrome. Prevalence and determinants of a bright liver echo pattern. Italian Journal of Gastroenterology and Hepatology 1997, 29:351-356.
164. Rudwill F., Bergouignan A., Gastebois C., et al. Effect of enforced physical inactivity induced by 60-d of bed rest on hepatic markers of NAFLD in healthy normal-weight women. Liver International 2015, 35:1700-1706.
165. Schult A., Eriksson H., Wallerstedt S., et al. Overweight and hypertriglyceridemia are risk factors for liver cirrhosis in middle-aged Swedish men. Scandinavian Journal of Gastroenterology 2011, 46:738-744.
166. Männistö V.T., Simonen M., Soininen P., et al. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. Journal of Lipid Research 2014, 55:2676-2684.
167. Corey K.E., Lai M., Gelrud L.G., et al. Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology 2012, 10:651-656.
168. Siddiqui M.S., Fuchs M., Idowu M., et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis associate with atherogenic lipoprotein profile. Clinical Gastroenterology and Hepatology 2014, 13.
169. Bhala N., Angulo P., van der Poorten D., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011, 54:1208-1216.
170. Loria P., Marchesini G., Nascimbeni F., et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014, 232:99-109.
171. Graham I., Cooney M.T., Bradley D., et al. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Current Cardiology Reports 2012, 14:709-720.
172. Lonardo A., Ballestri S., Targher G., et al. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2015, 9:629-650.
173. Tarugi P., Lonardo A., Ballarini G., et al. Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B. Gastroenterology 1996, 111:1125-1133.
174. Lonardo A., Lombardini S., Scaglioni F., et al. Hepatic steatosis and insulin resistance: does etiology make a difference. Journal of Hepatology 2006, 44:190-196.
175. Di Filippo M., Moulin P., Roy P., et al. Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia. Journal of Hepatology 2014, 61:891-902.
176. Promrat K., Kleiner D.E., Niemeier H.M., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51:121-129.
177. Harrison S.A., Fecht W., Brunt E.M., et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009, 49:80-86.
178. Glass L.M., Dickson R.C., Anderson J.C., et al. Total body weight loss of ≥10% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Digestive Diseases and Sciences 2015, 60:1024-1030.
179. Keating S.E., Hackett D.A., George J., et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of Hepatology 2012, 57:157-166.
180. Scaglioni F., Marino M., Ciccia S., et al. Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). Clinics and Research in Hepatology and Gastroenterology 2013, 37:353-358.
181. Haufe S., Haas V., Utz W., et al. Long-lasting improvements in liver fat and metabolism despite body weight regain after dietary weight loss. Diabetes Care 2013, 36:3786-3792.
182. Mummadi R.R., Kasturi K.S., Chennareddygari S., et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clinical Gastroenterology and Hepatology 2008, 6:1396-1402.
183. Lonardo A., Bellentani S., Ratziu V., et al. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies. Expert Review of Gastroenterology & Hepatology 2011, 5:279-289.
184. Lazo M., Solga S.F., Horska A., et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010, 33:2156-2163.
185. Bacchi E., Negri C., Targher G., et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology 2013, 58:1287-1295.
186. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. New England Journal of Medicine 2006, 355:2297-2307.
187. Klonoff D.C., Buse J.B., Nielsen L.L., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion 2008, 24:275-286.
188. Goh G.B., Pagadala M.R., Dasarathy J., et al. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver International 2015, 35:979-985.
189. Yokohama S., Yoneda M., Haneda M., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222-1225.
190. Georgescu E.F., Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. Journal of Gastrointestinal and Liver Diseases 2007, 16:39-46.
191. Georgescu E.F., Ionescu R., Niculescu M., et al. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World Journal of Gastroenterology 2009, 15:942-954.
192. Scorletti E., Bhatia L., McCormick K.G., et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: results from the *WELCOME study. Hepatology 2014, 60:1211-1221.
193. Argo C.K., Patrie J.T., Lackner C., et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. Journal of Hepatology 2015, 62:190-197.
194. Sanyal A.J., Abdelmalek M.F., Suzuki A., et al. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014, 147:377-384.
195. Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2013, 1:CD004816.
196. Eslami L., Merat S., Malekzadeh R., et al. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews 2013, 12:CD008623.
197. Park H., Shima T., Yamaguchi K., et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. Journal of Gastroenterology 2011, 46:101-107.
198. Takeshita Y., Takamura T., Honda M., et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 2014, 57:878-890.
199. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015, 385:956-965.
200. Ratziu V., Bellentani S., Cortez-Pinto H., et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. Journal of Hepatology 2010, 53:372-384.